Recombinant human thyrotropin preparation for adjuvant radioiodine treatment in children and adolescents with differentiated thyroid cancer

Daria Handkiewicz-Junak, Tomasz Gawlik, Jozef Rozkosz, Zbigniew Puch, Barbara Michalik, Elżbieta Gubala, Jolanta Krajewska, Aneta Kluczewska and Barbara Jarzab

Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Memorial Institute and Centre of Oncology, Gliwice Branch, Wybrzeze Armii Krajowej 14, 44-100 Gliwice, Poland

Abstract

Aim: Although recombinant human thyrotropin (rhTSH) is widely used in treating differentiated thyroid cancer (DTC), almost all clinical investigation has been in adults. The aim of our retrospective study was to evaluate outcomes of adjuvant, rhTSH-aided radioiodine treatment in children/adolescents with DTC and to compare them to 131I therapy during L-thyroxin withdrawal (THW).

Methods: Patients with the diagnosis of DTC who were ≤ 18 years of age and had no signs of persistent disease at the time of 131I treatment were included; 48 patients were treated after rhTSH (rhTSH group) and 82 after THW group. The median time of follow-up after therapy was 67 months and was longer in the THW group (99 vs 43 months, P < 0.05).

Results: On the day of 131I administration, all but one patient had TSH levels above 25 μIU/ml. Peak TSH concentration was significantly higher in the rhTSH group (152 μIU/ml vs 91 μIU/ml). Similarly, the thyroglobulin concentration was higher in the rhTSH group (9.7 ng/ml vs 1.8 ng/ml). No side effects requiring medical intervention were recorded after rhTSH administration. The evaluation of disease outcomes during TSH stimulation (6–18 months after 131I treatment) revealed equal rates of thyroid ablation (71%) in both groups. During subsequent follow-up, five patients showed recurrence (P > 0.05).

Conclusions: In children/adolescents, rhTSH-aided adjuvant radioiodine treatment is associated with rates of remnant ablation and short-term recurrence similar to THW. As this preparation has several advantages over THW, rhTSH may become the preferred method of TSH stimulation once studies of long-term outcomes show non-inferiority to THW in this age group.

Introduction

Initial treatment for patients with differentiated thyroid cancer (DTC) is total or near-total thyroidectomy, which is often followed by adjuvant radioactive iodine (131I) treatment (1, 2). The rationale for adjuvant radioiodine treatment is to decrease the risk of clinical tumour recurrence (3, 4) and improve the sensitivity and specificity of follow-up testing with serum thyroglobulin measurement and radioiodine scanning (5). To promote radioiodine uptake in the remaining normal thyroid and cancer cells, treatment is performed after stimulation of 131I uptake either with endogenous thyroid stimulating hormone (TSH) (after withdrawal of L-thyroxin) or exogenous stimulation with recombinant human thyrotropin (rhTSH). rhTSH enables patients to attain the TSH elevation necessary to optimize radioiodine treatment while sparing thyroidectomised patients hypothyroid morbidity (6) and extra-thyroidal radiation exposure (7, 8). rhTSH-aided adjuvant radioiodine
treatment has been proven a safe and effective therapy in adult DTC patients.

Most clinical studies and all regulatory approvals of rhTSH have been done in adults but not in children or adolescents (9). However, the potential of rhTSH-aided radioiodine therapy to decrease extra-thyroidal radiation exposure and hypothyroid morbidity is extremely important for the developing organism of young patients. Reports on the effectiveness and safety of 131I are not numerous, and only a few case reports and one small, retrospective study involving paediatric patients treated with rhTSH-aided adjuvant 131I have been published so far (10, 11, 12, 13).

Beginning in 1999, our centre started to offer rhTSH-aided radioiodine treatment as an adjunct to thyroid surgery or treatment of locoregional/metastatic DTC, first during an ‘off-label’ or ‘compassionate use’ program and subsequently on a regular basis. The decision of rhTSH or L-thyroxin withdrawal (THW) preparation for radioiodine treatment was left to the discretion of the treating physician and the patient. All radioiodine treatments, regardless of the method of preparation, were performed by the same nuclear medicine group following a standard protocol.

Herein, we have taken the opportunity to retrospectively review these two procedures and their clinical outcomes in children/adolescents diagnosed with DTC and treated with radioiodine as an adjunct to neck surgery. For the purpose of this study, adjuvant radioiodine treatment was defined as 131I treatment in DTC patients in whom primary tumour and metastatic lymph nodes were removed during primary neck surgery.

Subjects and methods

Patients

We retrospectively reviewed charts of DTC patients who were treated with radioactive iodine during the years 2000–2010. We searched for patients who were 18 years of age or younger during 131I treatment and had no signs of locoregional or distant disease on clinical or imaging examinations, confirming that the radioiodine treatment was an adjunct to the surgical treatment. Initially we identified 163 patients who were 18 years of age or younger at the time of their first 131I treatment; 130 (80%) of these children/adolescents fulfilled our inclusion criteria, e.g., had no clinical signs of persistent thyroid cancer at the time of 131I treatment. The data collected from medical charts included findings at diagnosis, surgery, 131I therapy, and outcome. The institutional ethics board approved this retrospective study on childhood thyroid cancer, and the requirement to obtain informed consent was waived.

In 48 (37%) patients, 131I therapy was performed after rhTSH stimulation (the rhTSH group) and in 82 (63%) after thyroid hormone withdrawal (the THW group). During the study period, the proportion of patients treated with rhTSH increased over time, and by 2008, the number of rhTSH procedures exceeded the number of endogenous TSH stimulation procedures.

The median age during 131I therapy was 15.6 years (range 6–18) and the majority of patients were girls. Before radioactive iodine therapy, all patients but one were treated with total/near total thyroidectomy. There were no significant intergroup differences in age, extent of surgery, histopathology, or primary tumour stage. All patients were free of persistent DTC, as confirmed by neck ultrasound, radiological, and scintigraphic examinations, during 131I therapy. The average interval between thyroid surgery and radioiodine therapy was 77 days, and this was significantly shorter in the rhTSH group (61 vs 88 days, P<0.005). Detailed characteristics of the study groups are provided in Table 1.

Radioiodine treatment procedure

Patients were treated according to a standard protocol with one- or two-stage total/near total thyroidectomy and adjuvant radioiodine therapy. In one patient, according to the surgeon, a subtotal thyroidectomy was performed, but on ultrasound examination thyroid remnants volume were 1.8 ml so reoperation was not recommended. The median interval between the last surgical intervention and 131I treatment was 77 days; however, in 10 cases it was more than 12 months, usually due to delayed referral for radioiodine treatment. Patients were treated with 131I after THW or rhTSH stimulation at the discretion of the treating physician and after a discussion with the patient and his or her parents. Thyroid hormone withdrawal lasted for 4 weeks, or 2 weeks in case of triiodothyronine (T3) pretreatment. Recombinant human TSH was administered according to a standard regimen (for details, see Supplementary Figure 1, see section on supplementary data given at the end of this article) and its application was approved by the local ethics committee.

Radioactive iodine activity was adjusted to the child’s age. Children <12 years old were administered 74–92.5 MBq/kg body weight, and older children had fixed activities of 2.2–3.7 GBq. According to standard
institutional practice, all patients were hospitalized in a radionuclide therapy ward with full radiation protection for at least 3 days after radioiodine administration and then discharged when the radiation dose rate at 1 m was ≤20 mSv/h. Post-therapy whole body scans (WBS) and, when required, spot or tomography imaging were performed 72 h after 131I treatment with a dual-head gamma camera (Multispect 2 or E. Cam-Duet, Siemens, Erlangen, Germany) equipped with parallel high-energy collimators.

**Patient follow-up**

After radiiodine treatment, all patients were advised to keep TSH levels within 0.1–0.4 μIU/ml. Stimulated thyroglobulin (Tg) and 131I WBS were performed 6–18 months after radioiodine treatment to assess the efficacy of the radioiodine treatment. Thereafter, all patients were followed-up with neck ultrasound, TSH, and Tg and Tg antibodies (TgAb) at 6- to 18-month intervals.

For thyroglobulin evaluation, only patients with negative thyroglobulin antibodies were included. Thyroglobulin concentrations were measured with an immunoradiometric (IRMA) assay DYNOtest Tg-S (Brahms; analytical sensitivity 0.05 ng/ml, functional sensitivity 0.3 ng/ml) until 2004. From January 2004 through May 2009, thyroglobulin was evaluated with a Timed Resolved Amplified Cryptate Emission assay (BRAHMS hTg KRYPTOR; analytical sensitivity 0.17 ng/ml, functional sensitivity 0.5 ng/ml) and, thereafter, with an Electrochemiluminescent Immunoassay (Roche Diagnostic, analytical sensitivity 0.1 ng/ml, functional sensitivity 1 ng/ml). Patients were considered as thyroglobulin-antibody free unless Tg recovery was >70% or <130% (institutional cut-off level; measurements performed until August 2006) or the TgAb concentration was detectable (<10 IU/ml, measurement performed from September 2006; BRAHMS TRACE assay; analytic sensitivity 10 IU/ml, functional sensitivity 33 IU/ml).

**Definitions of treatment outcomes**

For TgAb-negative patients, the following criteria were used to diagnose a complete remission of DTC: during TSH

<table>
<thead>
<tr>
<th>Clinical characteristics</th>
<th>All (n=130)</th>
<th>THW group (n=82)</th>
<th>rhTSH group (n=48)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Female</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age at DTC diagnosis (years)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>15.6 ± 2.6</td>
<td>15.5 ± 2.6</td>
<td>15.7 ± 2.6</td>
<td>NS</td>
</tr>
<tr>
<td>Extent of operation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total/near total thyroidectomy</td>
<td>130 (99%)</td>
<td>83 (100%)</td>
<td>47 (98%)</td>
<td>NS</td>
</tr>
<tr>
<td>DTC histopathology</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Papillary</td>
<td>85 (65%)</td>
<td>54 (66%)</td>
<td>31 (65%)</td>
<td>NS</td>
</tr>
<tr>
<td>Papillary follicular variant</td>
<td>31 (24%)</td>
<td>21 (26%)</td>
<td>10 (21%)</td>
<td>NS</td>
</tr>
<tr>
<td>Papillary (other variants)</td>
<td>7 (5%)</td>
<td>2 (2%)</td>
<td>5 (10%)</td>
<td>NS</td>
</tr>
<tr>
<td>Follicular</td>
<td>7 (5%)</td>
<td>5 (6%)</td>
<td>2 (4%)</td>
<td>NS</td>
</tr>
<tr>
<td>Primary tumour (UICC 2010)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1</td>
<td>60 (46%)</td>
<td>40 (49%)</td>
<td>20 (42%)</td>
<td>NS</td>
</tr>
<tr>
<td>T2</td>
<td>31 (24%)</td>
<td>18 (22%)</td>
<td>13 (27%)</td>
<td>NS</td>
</tr>
<tr>
<td>T3</td>
<td>24 (19%)</td>
<td>13 (16%)</td>
<td>11 (23%)</td>
<td>NS</td>
</tr>
<tr>
<td>T4</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>NS</td>
</tr>
<tr>
<td>Tx</td>
<td>15 (12%)</td>
<td>11 (13%)</td>
<td>4 (8%)</td>
<td>NS</td>
</tr>
<tr>
<td>Lymph nodes statusa</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N0</td>
<td>33 (25%)</td>
<td>20 (24%)</td>
<td>13 (27%)</td>
<td>NS</td>
</tr>
<tr>
<td>N1a</td>
<td>26 (20%)</td>
<td>16 (19%)</td>
<td>10 (21%)</td>
<td>NS</td>
</tr>
<tr>
<td>N1b</td>
<td>51 (39%)</td>
<td>32 (39%)</td>
<td>19 (40%)</td>
<td>NS</td>
</tr>
<tr>
<td>No lymph nodes dissection</td>
<td>20 (15%)</td>
<td>14 (17%)</td>
<td>6 (12%)</td>
<td>NS</td>
</tr>
<tr>
<td>Time from last thyroid surgery to 131I therapy (median; days)</td>
<td>77 (21–725)</td>
<td>88 (7–725)</td>
<td>61 (21–197)</td>
<td>0.005</td>
</tr>
<tr>
<td>131I activity in GBq (median)</td>
<td>3.7 (2.2–4.0)</td>
<td>3.7 (2.2–4.0)</td>
<td>3.7 (2.2–3.7)</td>
<td>NS</td>
</tr>
<tr>
<td>BMI (kg/m²; median)</td>
<td>20.9 (14.2–39.4)</td>
<td>21.0 (14.2–39.4)</td>
<td>20.8 (14.4–31.6)</td>
<td>NS</td>
</tr>
<tr>
<td>131I activity/BMI</td>
<td>2.9 (1.8–3.2)</td>
<td>2.9 (1.8–3.2)</td>
<td>2.9 (1.8–3.0)</td>
<td>NS</td>
</tr>
</tbody>
</table>

NS, not significant.

*aAlthough some patients suffered from lymph node metastases as confirmed in histopathology, metastatic lymph nodes were removed during operation, and during radiiodine treatment, none of the patients suffered from persistent, macroscopic disease.

| Clinical Study | D Handkiewicz-Junak and others | rhTSH in 131I treatment of children/adolescents with DTC | 173:6 | 875 |
stimulation: Tg below 2 ng/ml, no pathological (thyroid bed or metastases) uptake of $^{131}$I on WBS, and no signs of disease on neck ultrasound or other diagnostic examinations; during L-thyroxin treatment, patients were disease-free if Tg was below 1 ng/ml and there was no structural recurrence on neck ultrasound or radiological examinations. TgAb-positive DTC patients were diagnosed with a complete remission if there was no pathological (thyroid bed or metastases) uptake of $^{131}$I on WBS and there were no signs of disease on neck ultrasound or other diagnostic examinations.

### Statistical analysis

Descriptive analyses were performed to calculate means/medians depending on data distribution. Quantitative data with a normal distribution were compared with the Student’s $t$-test, while non-normally distributed data were compared using Wilcoxon signed rank tests. Categorical data or frequencies of events were compared using the Pearson $\chi^2$ or Fisher exact test (if the group number was less than 10). A $P$ value $<$0.05 was deemed significant. Analyses were performed using Statistica for Windows version 5.5PL (Statsoft, Tulsa, OK, USA). Percent/ages were rounded to the nearest whole number; therefore, totals exceed 100% for some parameters.

### Results

#### Radioactive iodine treatment

Administered activity of $^{131}$I did not differ between the rhTSH and THW group. On the day of $^{131}$I administration, all but one patient (in the THW group) had a TSH level above 25 $\mu$IU/ml. However, in the rhTSH group, the peak TSH concentration was significantly higher than in the THW group (Fig. 1). Peak TSH concentration on the day 3 of rhTSH stimulation showed a weak but significant inverse correlation with BMI (Supplementary Figure 2, see section on supplementary data given at the end of this article); no such correlation was seen in the THW group. In 17 patients (50% of the patients evaluated on day 6 of stimulation), TSH returned to normal limits by day 6 of rhTSH stimulation (Fig. 1) and was higher than 10 $\mu$IU/ml in only 4 patients.

Thyroglobulin antibodies were detected in 35 (23%) patients, either through direct TgAb measurement ($n=31$) or Tg recovery test ($n=4$). Thyroglobulin antibodies were more frequent in the rhTSH group (Fig. 2). After excluding patients with positive Tg antibodies, serum thyroglobulin concentration increased as a result of rhTSH stimulation and was the highest on day 6 of rhTSH stimulation (Fig. 3). Thyroglobulin in the THW group (measurements performed on the day of radiiodine treatment) was significantly lower than on day 6 of rhTSH stimulation but higher than on day 3 of rhTSH stimulation (Fig. 3).

Three days (or 72 h) after radiiodine administration, the radiation dose rate at 1 m was measured. The median radiation dose was 7 $\mu$Sv/h in the whole group of patients. There was a tendency for a higher dose rate in the THW group (median: THW 8 $\mu$Sv/h; rhTSH 6 $\mu$Sv/h); however, the difference was of borderline significance ($P=0.07$).

No side effects were recorded in medical charts after rhTSH administration. There was no increase in the free thyroid hormone ($fT_3$ and $fT_4$) concentration in the rhTSH treated group (Supplementary Figure 3, see section on supplementary data given at the end of this article).

#### Post $^{131}$I treatment evaluation during TSH stimulation

The median time between radioactive iodine treatment and evaluation of its outcome during TSH stimulation was 12 months. For most of the patients (105 (88%)), diagnostic examinations were performed after thyroid hormone withdrawal. In 15 (12%), rhTSH was used. Five patients from the rhTSH and five from the THW group were followed-up only while on L-thyroxin therapy and were not included in this sub-analysis.
From the 120 evaluated 131I WBS, thyroid remnant ablation was confirmed in 99 (83%) patients, and there was no difference in the ablation rate between groups previously treated with exogenous or endogenous TSH stimulation (Table 2).

Stimulated serum thyroglobulin and TgAb concentration was available for 117 out of 120 evaluated patients (97.5%); 84 (72%) were considered thyroglobulin antibody negative (Fig. 2). At that time, there was no difference in Tg antibody negativity between the rhTSH and thyroid THW groups. Considering patients without interfering thyroglobulin antibodies, 75% had thyroglobulin concentration below 1 ng/ml; this number increased to 83% for a Tg cut-off level below 2 ng/ml. The proportion of patients with low Tg was similar in the rhTSH and THW groups (Table 2).

Overall complete remission (scintigraphic and biochemical) was confirmed in 83 (71%) patients, and there was no difference in the remission rates between the THW and rhTSH groups. Similar rates of complete remission were observed when only patients without TgAb were analysed (Table 2).

The number of patients referred for 131I retreatment did not differ between the groups; 17 (22%) and 10 (23%) patients from the THW and rhTSH group, respectively, were referred for second radioiodine therapy (Table 3). The majority of retreatments were performed due to persistent radioiodine uptake in the thyroid bed or persistently increased Tg concentration. Six patients were retreated due to unequivocal results of WBS (suspicious uptake in the surgical bed after neck lymphadenectomy or in the upper mediastinum) during the first adjuvant radioiodine treatment. In two patients, who were retreated due to increasing Tg concentration, WBSs revealed lung metastases.

Follow-up during L-thyroxin treatment

The median time of follow-up from the time of 131I therapy to the last observation was 67 (12–153) months and was significantly longer in the THW group (99 vs 43 months, \( P<0.05 \)). During that time, five (3.8%) patients were diagnosed with structural DTC recurrence. Two patients were diagnosed with neck lymph node metastases (both in the THW group) 6 and 8 years after radioiodine treatment. Three other patients were diagnosed with lung metastases on WBSs performed after the second course of radioiodine therapy (one in the rhTSH and two in the THW group). In two patients, the second radioiodine treatment was performed 5–7 months after the first 131I therapy. The indications for therapy were a persistent uptake in the thyroid bed in one case and persistent Tg elevation in the second. In the third patient, lung recurrence was diagnosed 6 years after radioiodine treatment.

In four other patients (one in the THW and three in the rhTSH group), there was a persistent elevation of thyroglobulin levels (in three of them, there was also an
increase in TgAb concentration). Imaging studies including positron emission tomography with 18-FDG were negative for disease recurrence in these patients.

None of the patients developed a second neoplasm during the follow-up period.

Discussion

According to the American Thyroid Association (ATA) guidelines (2) and the European Consensus for the management of DTC (14), adjuvant radioiodine treatment is indicated for patients with large thyroid tumours, gross extra-thyroid extension, lymph node metastases, or other high-risk features. These indications are based on clinical studies showing reduced recurrence rate and mortality from DTC after $^{131}$I treatment (3, 4).

Although children/adolescents often present with advanced disease, due to their low mortality rate they are considered low risk. Hence, radioiodine treatment in this young group of DTC patients is questioned by some (15, 16) but supported by other authors (17, 18, 19, 20), who showed a decreased risk of DTC recurrence after radioiodine treatment. In the recent ATA Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer (9), $^{131}$I is indicated for treatment of iodine-avid persistent locoregional or nodal disease that cannot be resected as well as known or presumed iodine-avid distant metastases. One of the major issues raised by opponents of adjuvant radioiodine treatment in children/adolescents is the risk of secondary, radiation-related malignancies (9, 16).

The controversies over radioiodine treatment of children/adolescents with DTC concern also the preparation for the therapy, e.g., the use of recombinant human TSH. Opponents of its use claim that it may result in decreased effectiveness of radioiodine treatment. However, in the literature there are no data to support or reject this assumption. In contrast to the large number of studies showing the efficacy of rhTSH preparations for adjuvant radioiodine treatment in adults with DTC, data for children and adolescents are scarce. There are only a few patients described in the literature so far (11, 13). To our best knowledge, our retrospective study is the first that evaluated different aspects of the rhTSH-aided radioiodine therapy procedure and its outcomes in children and adolescents with DTC.

The main goal of our study was to compare treatment procedures and disease outcomes after adjuvant radioiodine treatment performed either after endogenous (THW group) or after exogenous TSH (rhTSH group) stimulation. The definition of adjuvant treatment means that all detectable disease had been removed during surgery, and during the $^{131}$I treatment, patients were free of macroscopic disease as confirmed by neck ultrasound and radiological and scintigraphic examinations. In agreement with reports of highly successful rhTSH-aided adjuvant radioiodine treatment in adult patients (1, 21, 22, 23, 24, 25), we did not find any significant difference

Table 2  Scintigraphic and biochemical evaluation (during TSH stimulation) performed 6–18 months after $^{131}$I therapy.

<table>
<thead>
<tr>
<th></th>
<th>All (n = 120)</th>
<th>THW group (n = 77)</th>
<th>rhTSH group (n = 43)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Scintigraphy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No radioiodine uptake (n = 120)</td>
<td>99 (83%)</td>
<td>63 (82%)</td>
<td>36 (84%)</td>
<td>NS</td>
</tr>
<tr>
<td>Persistent uptake in thyroid bed</td>
<td>21 (17.5%)</td>
<td>14 (18%)</td>
<td>7 (16%)</td>
<td>NS</td>
</tr>
<tr>
<td><strong>Biochemical evaluationa</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tg concentration (n = 84)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$&lt;2$ ng/ml</td>
<td>70/84 (83%)</td>
<td>53/62 (85%)</td>
<td>17/22 (77%)</td>
<td>NS</td>
</tr>
<tr>
<td>$\leq1$ ng/ml</td>
<td>63/84 (75%)</td>
<td>47/62 (76%)</td>
<td>16/22 (73%)</td>
<td>NS</td>
</tr>
<tr>
<td>Complete remission (scintigraphic and biochemical)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All patients (n = 117)</td>
<td>83/117 (71%)</td>
<td>53/75 (71%)</td>
<td>30/42 (71%)</td>
<td>NS</td>
</tr>
<tr>
<td>Patients with negative thyroglobulin antibody (n = 84)</td>
<td>62/84 (74%)</td>
<td>46/62 (74%)</td>
<td>16/22 (72%)</td>
<td>NS</td>
</tr>
</tbody>
</table>

NS, not significant.
aOnly patients with negative TgAb were included.

Table 3  Reason for $^{131}$I retreatment in THW and rhTSH group.

<table>
<thead>
<tr>
<th>Reason for $^{131}$I retreatment</th>
<th>All (n = 130)</th>
<th>THW group (n = 83)</th>
<th>rhTSH group (n = 48)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thyroid bed uptake with Tg $&lt;2$ ng/ml</td>
<td>9 (7%)</td>
<td>5 (%)</td>
<td>4 (8%)</td>
</tr>
<tr>
<td>Tg $&gt;2$ ng/ml</td>
<td>10 (8%)</td>
<td>7 (7%)</td>
<td>3 (6%)</td>
</tr>
<tr>
<td>Patients with Tg $&gt;2$ ng/ml</td>
<td>3 (2%)</td>
<td>3 (4%)</td>
<td>0</td>
</tr>
<tr>
<td>Unequivocal results of post-therapy $^{131}$I scan</td>
<td>4 (3%)</td>
<td>2 (2%)</td>
<td>2 (4%)</td>
</tr>
<tr>
<td>Late lung recurrence</td>
<td>1 (2%)</td>
<td>1 (2%)</td>
<td>0</td>
</tr>
<tr>
<td>All</td>
<td>27 (21%)</td>
<td>17 (20%)</td>
<td>10 (20%)</td>
</tr>
</tbody>
</table>
in childhood/adolescent DTC outcomes after $^{131}$I treatments performed with exogenous or endogenous TSH stimulation. Of note, there was no difference in the rate of thyroid remnant ablation and biochemical (serum Tg concentration) remission after radioiodine treatment of DTC childhood/adolescent patients prepared either by administering rhTSH or by withholding levothyroxine for endogenous TSH stimulation. There were also no differences in the rate of structural disease recurrence. However, it is important to point out that the follow-up period is relatively short in the rhTSH group and a longer time is necessary to confirm these findings. Patients diagnosed with DTC may relapse as long as 30 years after primary treatment (16, 26, 27), and in cases of cancer recurrence, they have a higher risk of death (27).

The only observed difference between the rhTSH and THW groups was a higher rate of TgAb positivity in the rhTSH group. However, a direct comparison is difficult as the method of assessment of Tg antibodies changed during the study period. Until 2006, we evaluated Tg antibodies indirectly, by the Tg recovery test with an institutional cut-off level of 70–130%. Thereafter, direct TgAb measurement, with the lowest detection level of 10 IU/ml, was introduced. The cut-off level of 10 IU/ml for direct Tg measurement is much more rigorous than our institutional Tg recovery limits. Therefore, we studied the results of these two methods separately. However, we observed a higher rate of Tg antibody positivity in the rhTSH group during $^{131}$I treatment, regardless of the method of measurement used. This may be due to a shorter time between surgery and $^{131}$I treatment in the rhTSH group (61 in the rhTSH vs 88 days in the THW group).

The success of radioiodine treatment can also be measured as the rate of $^{131}$I retreatments. Although the decision to undergo a second course of $^{131}$I remained at the discretion of the treating physician, there was no difference between the THW and rhTSH group in the rates of retreatments. Of 130 patients, 23 (21%) were referred for secondary radioiodine treatment. In a recent study by Mihailovic et al. (20), 43% of paediatric patients treated with radioiodine after thyroxin withdrawal received at least two courses of $^{131}$I treatment; however, their study also included patients with metastatic disease.

In our study, we did not intend to evaluate the role of radioiodine treatment or prognosis of childhood/adolescent DTC, as it was reported recently by several studies (15, 16, 17, 18, 28). However, we have to underline here that the relatively low number (3.8%) of disease recurrences is probably a result of not only extensive treatment of our study group but also our inclusion criteria. Only patients with adjuvant radioiodine treatment were included, and patients with persistent locoregional or distant metastases during $^{131}$I therapy were excluded.

Due to the retrospective nature of our study, patients did not complete any side effect-oriented questionnaires, yet in the medical records, we did not find any information on side effects such as headache or nausea, which have been reported by some paediatric DTC patients after rhTSH stimulation (29). We can only speculate that, due to the mild nature of the side effects, they were not reported during routine ward rounds. However, in one girl with disseminated DTC (a case not included in this study), a skin rash developed after rhTSH administration.

Use of rhTSH in preparation for radioiodine therapy has several advantages over thyroid hormone withdrawal. Recombinant human TSH-aided radioiodine treatment allows for lower radiation exposure of extra-thyroidal compartments of the body during $^{131}$I therapy due to lower levels (about 30% on average) of radioactivity in the blood. These findings can be explained by a non-disturbed renal clearance of radioiodine in the euthyroid state (7, 30, 31). As a consequence of decreased whole body radiation exposure, at least in theory, there is a lower risk of secondary cancers after radioiodine therapy. This hypothesis is supported by a study showing that the rate of chromosomal translocation is significantly lower in radioiodine-treated patients after preparation with rhTSH than after THW (32). In our retrospective study, we did not have data on radiation exposure during rhTSH or THW preparation. However, we were able to compare the radiation dose rates at 1 m, which may serve as a surrogate for radiation exposure of the patient. Although only borderline significant, the measurements performed 72 h after $^{131}$I administration showed a tendency toward a lower dose rate in the rhTSH group. This finding supports the idea that rhTSH decreases radiation exposure to patients during rhTSH treatment.

An additional advantage of radioiodine treatment under recombinant TSH stimulation is the avoidance of hypothyroid morbidity. Although we did not have data to evaluate this aspect in our retrospective study, avoidance of hypothyroid morbidity is appealing in young, physically and mentally developing patients. Reductions in radiation exposure and avoidance of hypothyroid morbidity were the main reasons we decided to use rhTSH during radioiodine therapy because we were not able to be reimbursed for both therapy and diagnostic
It is only during the last 5 years that we have received sufficient funding to perform all TSH stimulation procedures in DTC children/adolescents with rhTSH.

Although our study showed that the results of adjuvant radioiodine treatment of childhood DTC did not depend on the type of TSH stimulation, this study had several limitations. This was a nonrandomised, uncontrolled retrospective study based on a medical charts review, and therefore, some aspects of rhTSH administration, e.g., side effects, might be underestimated. We cannot rule out selection bias toward THW preparation in patients with more advanced disease during surgical intervention. Additionally, the number of patients in the rhTSH group is rather low so one cannot exclude the possibility that a larger group of patients and a longer time of follow-up will show differences in outcomes between rhTSH and THW stimulation. Of note is also the fact that our study only evaluated selected cases without any evidence of persistent disease during $^{131}$I, so one cannot extend the results to more advanced cases.

Conclusions

In accordance with data from adults with DTC, our study findings demonstrated that in children and adolescents, rhTSH-aided adjuvant radioiodine treatment is associated with rates of scintigraphic thyroid ablation, biochemical remission, and short-term recurrence rates similar to traditional THW. As this preparation has several advantages over $\mathrm{L}$-thyroxin withdrawal, rhTSH may become the preferred method of TSH stimulation once long-term follow-up demonstrates non-inferiority to THW in this age group.

Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/EJE-15-0562.

Declaration of interest
Daria Handkiewicz-Junak, Jolanta Krajewska, and Barbara Jarzab received travel grants from Genzyme.

Funding
This research study did not receive any specific grant from any funding agency in the public, commercial, or not-for-profit sector.

References


2 Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M \textit{et al}.
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. \textit{Thyroid} 2009 \textbf{19} 1167–1214. (doi:10.1089/thy.2009.0110)

3 Mazzaferri EL \\& Jhiang SM.
Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. \textit{American Journal of Medicine} 1994 \textbf{97} 418–428. (doi:10.1016/0002-9343(94)90321-2)

4 Sawka AM, Thephamongkol K, Brouwen M, Thabane L, Browman G \& Gerstein HC.


6 Dow KH, Ferrell BR \\& Anello C.

Iodine biokinetics and dosimetry in radiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. \textit{Journal of Nuclear Medicine} 2006 \textbf{47} 648–654.


Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer The American Thyroid Association Guidelines Task Force on Pediatric Thyroid Cancer. \textit{Thyroid} 2015 \textbf{25} 716–759. (doi:10.1089/thy.2014.0460)

10 Joransky S, Herzovich V, Qualey RR \\& Tuttle RM.


12 Ratli M, Cohan P \\& Lee K.

13 Rosario PW, Mineiro Filho AF, Lacerta RX \\& Calsolari MR.


Hanscheid H, Verburg FA, Biko J, Diessel I, Demidchik YE, Drozd V & Reiners C. Success of the postoperative 131I therapy in young Belarusian patients with differentiated thyroid cancer after Chernobyl depends on the radiation absorbed dose to the blood and the thyroglobulin level. European Journal of Nuclear Medicine and Molecular Imaging 2011 38 1296–1302.


Hugo J, Robenschot E, Gewarl R, Larson S & Tuttle RM. Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence. Thyroid 2012 22 1007–1015. (doi:10.1089/thy.2012.0183)

Tuttle RM, Lopez N, Leboeuf R, Minkowitz SM, Gewarl R, Brokhin M, Omry G & Larson S. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function. Thyroid 2010 20 257–263. (doi:10.1089/thy.2009.0401)


